Catalyst Brief

← Calendar

Readoutin 45d

Regeneron Pharmaceuticals — Fianlimab

Phase 3 primary completion: A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery.

Date
Jan 2027
Type
Readout
Indication
Melanoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.